
The FDA approves oral SERD giredestrant for ESR1-mutated breast cancer after a 62% risk cut, tying supply to testing ahead of a November 30, 2026 adjuvant decision.
This comparative study suggests that pregelatinized starches are superior to natural starches in terms of improving the plastic deformation in tablet formulations during compression.
about 25 years ago
Evaluation of Gelatins for Cross-Linking Potentialabout 25 years ago
Fast-Melting Tablets: Developments and Technologiesabout 25 years ago
Compendium of Pharmaceutical Excipients for Vaginal Formulations





